中國醫藥大學機構典藏 China Medical University Repository, Taiwan:Item 310903500/58538
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 29490/55136 (53%)
Visitors : 1904084      Online Users : 434
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/58538


    Title: 以Infliximab為例探討生物相似藥對於德國、美國及台灣健保支出的影響
    The impact of biosimilar on health care expenditure in Germany, the United States and Taiwan: A case study for Infliximab biosimilar (Remsima ,Inflectra ,Flixabi and Renflexis )
    Authors: 陳靜秀;Ching-Hsiu Chen
    Contributors: 製藥碩士學位學程
    Keywords: 生物相似藥;健康保險;Infliximab;biosimilar;health insurance
    Date: 2018-08-02
    Issue Date: 2018-12-25 10:14:46 (UTC+8)
    Publisher: 中國醫藥大學
    Appears in Collections:[Master Program for Pharmaceutical Manufacture] Theses & dissertations

    Files in This Item:

    File SizeFormat
    index.html0KbHTML104View/Open


    All items in CMUR are protected by copyright, with all rights reserved.

     

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback